摘要
与具有相似合并症的非糖尿病患者相比,糖尿病患者发生心力衰竭的风险高 2-5 倍。最近的报告表明,近一半的糖尿病人群仍未确诊,使糖尿病心肌病 (DCM) 成为临床相关实体。在心肌中,慢性高血糖引起以心室扩张、舒张功能障碍、纤维化和肥大为特征的结构和功能异常,导致心力衰竭。由于糖尿病是一种多因素异质性代谢紊乱,不能与冠状动脉疾病或高血压一起诊断或控制,因此迫切需要了解导致 DCM 的潜在分子机制并确定潜在的治疗靶点。小的非编码 RNA,特别是微小 RNA (miRNA),已成为包括 DCM 在内的多种危及生命的疾病的关键调节因子。最近的研究报道,miRNA 不仅调节 DCM 的基本机制,如胰岛素抵抗、MAPK 通路、PI3K-AkT 通路、氧化应激以及炎症信号传导,而且还具有成为治疗或诊断靶点的潜力。本综述研究了关键 miRNA 在 DCM 发病和发病机制中的作用,这也描述了在临床前研究中作为治疗和诊断分子的巨大潜力。此外,它强调了全球范围内已完成和正在进行的糖尿病和 miRNA 临床试验,以提供对即将到来的 miRNA 疗法的展望。
关键词: 糖尿病、糖尿病性心肌病、MicroRNA、治疗学、临床试验、关键miRNA。
图形摘要
Current Gene Therapy
Title:MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Volume: 21 Issue: 4
关键词: 糖尿病、糖尿病性心肌病、MicroRNA、治疗学、临床试验、关键miRNA。
摘要: The risk of heart failure is 2-5 times higher in diabetic patients as compared to non-diabetic patients with similar comorbidities. Recent reports suggest that nearly half of the diabetic population remains undiagnosed, making diabetic cardiomyopathy (DCM) a clinically relevant entity. In the myocardium, chronic hyperglycemia elicits structural and functional abnormalities characterized by ventricular dilation, diastolic dysfunction, fibrosis, and hypertrophy leading to heart failure. Since diabetes is a multifactorial heterogeneous metabolic disorder which cannot be diagnosed or controlled along with coronary artery disease or hypertension, there is an urgent need to understand the underlying molecular mechanisms that leads to DCM and identify potential therapeutic targets. Small non-coding RNAs, in particular, microRNAs (miRNAs), have emerged as key regulators for several life-threatening diseases, including DCM. Recent studies have reported that miRNAs not only regulate the fundamental mechanisms of DCM such as insulin resistance, MAPK pathway, PI3K-AkT pathway, oxidative stress, also inflammatory signaling, but also possess the potential to be a therapeutic or diagnostic target. This review examines the role of critical miRNAs in the onset and pathogenesis of DCM, which also depicts high potential as therapeutic and diagnostic molecule in preclinical studies. Further, it highlights the completed and on-going clinical trials around the globe for diabetes and miRNAs to provide a outlook about the upcoming miRNA therapeutics.
Export Options
About this article
Cite this article as:
MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy, Current Gene Therapy 2021; 21 (4) . https://dx.doi.org/10.2174/1566523221666210311111619
DOI https://dx.doi.org/10.2174/1566523221666210311111619 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Evaluation of Cardiac Scan in Diagnosing Coronary-artery Disease
Current Medical Imaging Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology The Bioenergetics of Isolated Mitochondria from Different Animal Models for Diabetes
Current Diabetes Reviews Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure
Current Medicinal Chemistry Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Nitric Oxide in Cardiac Transplantation
Vascular Disease Prevention (Discontinued) Mitochondrial Superoxide Dismutase - Signals of Distinction
Anti-Cancer Agents in Medicinal Chemistry Fetal Risks of Maternal Diabetes
Current Women`s Health Reviews Effects of Apelin Peptides on Diabetic Complications
Current Protein & Peptide Science Thrombotic Thrombocytopenic Purpura and Anti-Thrombotic Therapy Targeted to Von Willebrand Factor
Current Vascular Pharmacology Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Antibodies Against G-Protein Coupled Receptors: Novel Uses in Screening and Drug Development
Combinatorial Chemistry & High Throughput Screening A Novel, Biodegradable, Thermoresponsive Hydrogel Attenuates Ventricular Remodeling and Improves Cardiac Function Following Myocardial Infarction - a review
Current Pharmaceutical Design Chlorogenic Acid Suppresses a Cell Adhesion Molecule in Experimental Autoimmune Myocarditis in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)